PMGC Holdings Inc. (ELAB) Stock Ticker
Market factors today
Unlock the full ELAB picture
About PMGC Holdings Inc.
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
ELAB stock facts
| Ticker symbol | ELAB |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.1M |
| CEO | Graydon Bensler |
| Employees | 33 |
| Headquarters | Newport Beach, CA, US |
| IPO date | 2023-11-21 |
| Website | pmgcholdings.com |
What you can see for ELAB on Tickr
Live ELAB price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ELAB report.
Rankings
FAQ
What is the ticker symbol for PMGC Holdings Inc.?
The ticker symbol for PMGC Holdings Inc. is ELAB, listed on the NASDAQ Capital Market.
What is ELAB?
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core…